Mycophenolate mofetil Active Not Recruiting Phase 2 Trials for Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Recurrent Mantle Cell Lymphoma / Myelodysplastic Syndrome / Acute Myeloid Leukemia With FLT3/ITD Mutation / Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2); GATA2, MECOM / Acute Myeloid Leukemia With Inv(3)(q21q26.2); RPN1-EVI1 / Recurrent Follicular Lymphoma / B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Adult Acute Lymphoblastic Leukemia in Complete Remission / Burkitt's Lymphoma / Recurrent Marginal Zone Lymphoma / Refractory Plasma Cell Myeloma / Childhood Acute Lymphoblastic Leukemia in Complete Remission / Recurrent Anaplastic Large Cell Lymphoma / Acute Megakaryoblastic Leukemia / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Acute Undifferentiated Leukemia (AUL) / Acute Erythroid Leukemia in Remission / Recurrent Plasma Cell Myeloma / B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1) / Acute Myeloid Leukemia With Inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 / Acute myeloid leukaemia (in remission) / DS Stage II Plasma Cell Myeloma / Acute Myeloid Leukemia With t(6;9)(p23;q34); DEK-NUP214 / Recurrent Diffuse Large B-Cell Lymphoma / Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214 / Acute Leukemia in Remission / T Lymphoblastic Lymphoma / Acute Myeloid Leukemia With Multilineage Dysplasia / DS Stage III Plasma Cell Myeloma / Recurrent Hodgkin Lymphoma / Secondary Acute Myeloid Leukemia (Secondary AML, sAML) / Acute Biphenotypic Leukemia (ABL) Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00793572Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma